ArticlePharmacotherapy2025
Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients.
Article in Pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntravenous regular insulin is often used for the management of hyperkalemia due to its rapid onset of action and predictable potassium-lowering effects. Various studies have been conducted to determine optimal insulin dosing strategies that reduce serum potassium levels without increasing hypoglycemia risk. As data shifts towards lower or fixed insulin doses, validating the appropriateness of these dosing regimens for the management of hyperkalemia in overweight patients is warranted. The purpose of this study was to evaluate the serum potassium-lowering effects of 5 units versus 10 units of intravenous regular insulin in hyperkalemic patients with a body mass index (BMI) ≥ 25 kg/m
methodsA multicenter, retrospective study was performed in adult patients with BMI ≥ 25 kg/m
resultsOf 699 patients screened, 81 patients received 5 units and 81 patients received 10 units. There was no difference in the serum potassium-lowering effects of 5 units versus 10 units of intravenous regular insulin (0.5 (0.1-1.1) mmol/L vs. 0.5 (0.2-1) mmol/L; p = 0.65). No significant differences were observed for any secondary outcomes. Subgroup analyses revealed no significant differences for BMI; the number of concomitant acute potassium-lowering therapies received; or the degree of renal impairment, aside from a significantly larger potassium-lowering effect with 10 units of intravenous regular insulin observed in the subgroup receiving no concomitant acute potassium-lowering therapies as well as the subgroup with a creatinine clearance of 30-60 mL/min.
conclusionIn this small, retrospective cohort study, treatment with 5 units of intravenous regular insulin did not compromise the serum potassium-lowering effect when compared to 10 units in overweight patients with hyperkalemia. Further controlled studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.